Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Trintellix generic availability us 2026?Us patent application biosynthesis of heparin?Mycophenolate 500 mg coupon?Cefadroxil market share?Gabapentin enacarbil?
See the DrugPatentWatch profile for Tivicay
Tivicay is an antiretroviral medicine in the integrase strand transfer inhibitor (INSTI) drug class. It treats HIV-1 by blocking the HIV integrase enzyme, which the virus needs to insert (integrate) its genetic material into a host cell’s DNA [1].
As an INSTI, Tivicay is used as part of combination antiretroviral therapy (ART). INSTIs are designed to stop a key step in HIV replication (integration), which helps reduce viral load and control infection [1].
Tivicay is usually prescribed alongside other antiretroviral drugs (different classes) as combination therapy, rather than as a single agent. The exact regimen depends on factors like treatment history and resistance testing [1].
Yes. Other INSTIs include medicines such as bictegravir and cabotegravir, which work by targeting the HIV integrase pathway in a similar way [1]. Sources: [1] https://www.drugs.com/tivicay.html
Other Questions About Tivicay :